Hepatitis C: Epidemiology, diagnosis, natural history and therapy

Contributions to Nephrology

Volumn 176, Issue , 2012, Pages 1-9

  Pol, Stanislas ^a   Vallet Pichard, Anaïs ^a   Corouge, Marion ^a   Mallet, Vincent O ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; RIBAVIRIN;

CHRONIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; PREVALENCE; REVIEW; VIROLOGY;

ANTIVIRAL AGENTS; CHRONIC DISEASE; HEPACIVIRUS; HEPATITIS C; HUMANS; INCIDENCE; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; PREVALENCE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84856903165     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000332374     Document Type: Review

References (28)

1. Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-567. (Pubitemid 41196755)
2. Lavanchy D: The global burden of hepatitis C. Liver Int 2009;29:74-81.
3. Esteban JI, Sauleda S, Quer J: The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008, 48:148-62. (Pubitemid 350191999)
4. Kamal SM, Nasser IA: Hepatitis C genotype 4: what we know what we don t yet know. Hepatology 2008;47:1371-1383. (Pubitemid 351547923)
5. van de Laar TJW, Matthews GV, Prins M, et al: Acute hepatitis C in HIV- infected men who have sex with men: an emerg-ing sexually transmitted infection. AIDS 2010;24:1799-1812.
6. Jadoul M, Cornu C, van Ypersele de Strihou C: Universal precautions prevent hepatitis C virus transmission: a 54 month follow- up of the Belgian Multicenter Study. The Universitaires Cliniques St- Luc (UCL) Collaborative Group. Kidney Int 1998;53:1022-1025. (Pubitemid 28155679)
7. Antaki N Craxi A, Kamal S, Moucari R, Van de Merwe S, Haffar S, et al: The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010;30:342-355.
8. EASL Clinical Practice Guidelines: Management of Hepatitis C virus infection. J Hepatol August 2011;55:245-264.
9. Santantonio T, Wiegang J, Gerlac JT: Acute hepatitis C: current status and remaining challenges. J Hepatol 2008;49:625-633.
10. Thomas DL, Thio CL, Martin MP, et al: Genetic variation in IL28B and spontane-ous clearance of hepatitis C virus. Nature 2009;461:798-801.
11. Afdhal NH: The natural history of hepatitis C. Semin Liver Dis 2004;24:3-8. (Pubitemid 39180700)
12. Yang YD, Roberts LR: Hepatocellular carci-noma: a global view. Nat Rev Gastroenterol Hepatol 2010;7:448-458.
13. Manns MP, McHutchison JG, Gordon SC, et al: Peginterferon alfa- 2b plus ribavirin com-pared with interferon alfa- 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965. (Pubitemid 32913521)
14. Fried MW, Shiffman ML, Reddy KR, et al: Peginterferon alfa- 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
15. Hadziyannis SJ, Sette H Jr, Morgan TR et al: Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment dura-tion and ribavirin dose. Ann Intern Med 2004;140:346-355.
16. Kamal S, El Tawil AA, Nakano T, et al: Peginterferon alpha- 2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinet-ics on sustained virological response. Gut 2005;54:858-866. (Pubitemid 40732106)
17. Davis GL, Wong JB, McHutchison JG, et al: Early virologic response to treatment with peginterferon alfa- 2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652. (Pubitemid 37052151)
18. Zeuzem S, Buti M, Ferenci P et al: Efficacy of 24 weeks treatment with peginterferon alfa- 2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103. (Pubitemid 41772522)
19. Reddy KR, Hadziyannis SJ, Diago M, et al: The influence of cumulative peginterferon alpha- 2a (40 kDa) and ribavirin (RBV) expo-sure on sustained virological response (SVR) rates in patients with genotype 1 chronic hepatitis C. J Hepatol 2005;42:217-217.
20. Shiffman ML, Salvatore J, Hubbard S, et al: Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46:371-379. (Pubitemid 47344771)
21. Fontaine H, Chaix ML, Lagneau JL, et al: Recovery from hepatitis C in long- term responders to ribavirin plus interferon alfa. Lancet 2000;356:41. (Pubitemid 30416995)
22. Poynard T, McHutchison J, Davis GL, Esteban- Mur R, Goodman Z, Bedossa P et al: Impact of interferon α- 2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131-1137.
23. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet- Pichard A, Fontaine H, et al: The relationship of regression of cirrho-sis to outcome in chronic hepatitis C. Ann Intern Med 2008;149:399-403.
24. Mc Hutchison JG, Everson GT, Gordon SC, et al: Telaprevir with peginterferon and riba-virin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838.
25. Hezode C, Forestier N, Dusheiko G, et al: Telaprevir and peginterferon with or without ribavirin for chronic HCV genotype 1 infec-tion. N Engl J Med 2009;360:1839-1850.
26. Kwo PY, Lawitz EJ, McCone J, et al: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginter-feron alpha- 2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT- 1): an open- label, ran-domised, multicentre phase 2 trial. Lancet 2010;376:705-716.
27. McHutchison JG, Manns MP, Muir AJ, et al: Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303.
28. Bacon BR, Gordon SC, Lawitz E, Marcellin P Vierling JM, Zeuzem S, et al: Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.